JP6599908B2 - ニューロテンシン受容体１の小分子アゴニスト - Google Patents
ニューロテンシン受容体１の小分子アゴニスト Download PDFInfo
- Publication number
- JP6599908B2 JP6599908B2 JP2016574242A JP2016574242A JP6599908B2 JP 6599908 B2 JP6599908 B2 JP 6599908B2 JP 2016574242 A JP2016574242 A JP 2016574242A JP 2016574242 A JP2016574242 A JP 2016574242A JP 6599908 B2 JP6599908 B2 JP 6599908B2
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- methyl
- piperidin
- quinazolin
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462017046P | 2014-06-25 | 2014-06-25 | |
| US62/017,046 | 2014-06-25 | ||
| PCT/US2015/037515 WO2015200534A2 (en) | 2014-06-25 | 2015-06-24 | Small molecule agonists of neurotensin receptor 1 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017519772A JP2017519772A (ja) | 2017-07-20 |
| JP2017519772A5 JP2017519772A5 (enExample) | 2018-08-09 |
| JP6599908B2 true JP6599908B2 (ja) | 2019-10-30 |
Family
ID=54938931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016574242A Active JP6599908B2 (ja) | 2014-06-25 | 2015-06-24 | ニューロテンシン受容体１の小分子アゴニスト |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US10118902B2 (enExample) |
| EP (1) | EP3160961B1 (enExample) |
| JP (1) | JP6599908B2 (enExample) |
| CA (1) | CA2952732C (enExample) |
| WO (1) | WO2015200534A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004011217B4 (de) | 2004-03-04 | 2006-11-30 | Dr. Osypka Gmbh | Vorrichtung zum Implantieren einer Herzschrittmacher - und/oder Defibrillations-Elektrode |
| WO2014100501A1 (en) | 2012-12-20 | 2014-06-26 | Sanford-Burnham Medical Research Institute | Small molecule agonists of neurotensin receptor 1 |
| US10118902B2 (en) | 2014-06-25 | 2018-11-06 | Sanford Burnham Prebys Medical Discovery Institute | Small molecule agonists of neurotensin receptor 1 |
| JP6882289B2 (ja) * | 2015-11-25 | 2021-06-02 | コンバージーン・リミテッド・ライアビリティ・カンパニーＣｏｎｖｅｒｇｅｎｅ Ｌｌｃ | 二環式ｂｅｔブロモドメイン阻害剤及びその使用 |
| CN107903209B (zh) * | 2017-12-29 | 2021-05-14 | 宁夏忠同生物科技有限公司 | 一种2-氨基-5-氟吡啶-3-甲酸甲酯的合成方法 |
| CN109251196B (zh) * | 2018-01-24 | 2020-11-13 | 浙江工业大学 | 氨基苯并[d]氮杂*基喹唑啉类化合物及其制备方法和应用 |
| EP4225285A4 (en) * | 2020-10-06 | 2024-11-20 | D.E. Shaw Research, LLC | LACTAM COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS |
| US20240398806A1 (en) * | 2021-05-13 | 2024-12-05 | Duke University | Compositions For and Methods of Treating and/or Preventing Pain |
| US12091454B2 (en) | 2022-12-28 | 2024-09-17 | Development Center For Biotechnology | Humanized anti-human neurotensin receptor 1 antibodies and their uses |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58172379A (ja) | 1982-04-02 | 1983-10-11 | Showa Denko Kk | 新規なキナゾリン誘導体 |
| WO1994019342A1 (fr) | 1993-02-18 | 1994-09-01 | Kyowa Hakko Kogyo Co., Ltd. | Inhibiteur de l'incorporation d'adenosine |
| US5866562A (en) | 1996-10-25 | 1999-02-02 | Bayer Aktiengesellschaft | Ring-bridged bis-quinolines |
| CN1474815A (zh) | 2000-09-20 | 2004-02-11 | Ĭ��ר���ɷ�����˾ | 4-氨基-喹唑啉 |
| US7713983B2 (en) | 2003-03-03 | 2010-05-11 | Vertex Pharmaceuticals Incorporated | Quinazolines useful as modulators of ion channels |
| JP2007510642A (ja) * | 2003-11-03 | 2007-04-26 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 中枢神経系障害の治療のための新規ノルエピネフリン再取込み阻害薬 |
| WO2006007864A1 (en) | 2004-07-17 | 2006-01-26 | Max Planck Geselllschaft Zur Förderung Der Wissenschaft | Treating neurodegenerative conditions |
| US20070197509A1 (en) | 2005-12-21 | 2007-08-23 | Painceptor Pharma Corporation | Compositions and methods for modulating gated ion channels |
| US8153803B2 (en) | 2006-07-18 | 2012-04-10 | The General Hospital Corporation | Compositions and methods for modulating sirtuin activity |
| AU2008345225A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| WO2011153553A2 (en) * | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| CN102786483B (zh) | 2011-05-19 | 2016-03-30 | 复旦大学 | 4-（4-苯基哌嗪基）喹唑啉类衍生物的药用用途 |
| US9914730B2 (en) * | 2012-09-28 | 2018-03-13 | Cancer Research Technology Limited | Azaquinazoline inhibitors of Atypical protein Kinase C |
| WO2014100501A1 (en) | 2012-12-20 | 2014-06-26 | Sanford-Burnham Medical Research Institute | Small molecule agonists of neurotensin receptor 1 |
| US10118902B2 (en) | 2014-06-25 | 2018-11-06 | Sanford Burnham Prebys Medical Discovery Institute | Small molecule agonists of neurotensin receptor 1 |
-
2015
- 2015-06-24 US US15/319,329 patent/US10118902B2/en active Active
- 2015-06-24 CA CA2952732A patent/CA2952732C/en active Active
- 2015-06-24 WO PCT/US2015/037515 patent/WO2015200534A2/en not_active Ceased
- 2015-06-24 EP EP15811366.2A patent/EP3160961B1/en active Active
- 2015-06-24 JP JP2016574242A patent/JP6599908B2/ja active Active
-
2018
- 2018-09-24 US US16/140,363 patent/US10584103B2/en active Active
-
2020
- 2020-01-14 US US16/742,431 patent/US11261164B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3160961A2 (en) | 2017-05-03 |
| WO2015200534A2 (en) | 2015-12-30 |
| CA2952732A1 (en) | 2015-12-30 |
| US20170240514A1 (en) | 2017-08-24 |
| EP3160961B1 (en) | 2021-09-01 |
| US20190023665A1 (en) | 2019-01-24 |
| US10584103B2 (en) | 2020-03-10 |
| WO2015200534A3 (en) | 2016-04-21 |
| US11261164B2 (en) | 2022-03-01 |
| US20200354324A1 (en) | 2020-11-12 |
| JP2017519772A (ja) | 2017-07-20 |
| US10118902B2 (en) | 2018-11-06 |
| CA2952732C (en) | 2024-01-02 |
| EP3160961A4 (en) | 2018-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6599908B2 (ja) | ニューロテンシン受容体１の小分子アゴニスト | |
| CA2895129C (en) | Quinazoline neurotensin receptor 1 agonists and uses thereof | |
| CA2957046C (en) | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | |
| BR112020026748A2 (pt) | Inibidores de quinases dependentes de ciclina | |
| JP4173191B2 (ja) | Ｈ３リガンドとして有用な３‐または４‐一置換フェノールおよびチオフェノール誘導体 | |
| JP6477484B2 (ja) | 含硫黄二環式化合物 | |
| CA2962917C (en) | Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms) | |
| CA2824536A1 (en) | Protease activated receptor 2 (par2) antagonists | |
| CA2902656A1 (en) | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine d3 receptor | |
| US7649002B2 (en) | (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists | |
| US12427159B2 (en) | Hydroxypyrrolidine-substituted arylsulfonamide compounds with selective activity in voltage-gated sodium channels | |
| KR20180100705A (ko) | 신규 화합물 및 이의 약학적으로 허용 가능한 염 | |
| WO2024079351A1 (en) | Novel piperazine-based sulfonamides and their use as neuroprotective and/or neurorestorative agents | |
| WO2024121709A1 (en) | Papain-like protease (plpro) inhibitors | |
| ES2364254T3 (es) | Piperidinilcarbonil pirrolidinas y su uso como agonistas de melanocortina. | |
| MXPA06008934A (en) | Piperidinylcarbonyl-pyrrolidines and their use as melanocortin agonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170206 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180621 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180621 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20181227 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190118 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190410 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190528 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190911 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20191003 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6599908 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |